Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
2. Revaprazan Hydrochloride
3. Yh 1885
4. Yh-1885
1. 199463-33-7
2. Revaprazan [inn]
3. N-(4-fluorophenyl)-4,5-dimethyl-6-(1-methyl-3,4-dihydroisoquinolin-2(1h)-yl)pyrimidin-2-amine
4. Yh-1885 Free Base
5. 199463-33-7 (free Base)
6. Sb-641257
7. 5p184180p5
8. Unii-5p184180p5
9. Revaprazan [mi]
10. Sb 641257
11. Revaprazan [mart.]
12. N-(4-fluorophenyl)-4,5-dimethyl-6-(1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)pyrimidin-2-amine
13. Revaprazan [who-dd]
14. Schembl2194461
15. Chembl1618279
16. Gtpl12007
17. Dtxsid10870216
18. Chebi:135529
19. Ex-a5099
20. Ncgc00408843-01
21. 4-(3,4-dihydro-1-methyl-2(1h)-isoquinolinyl)-n-(4-fluorophenyl)-5,6-dimethyl-2-pyrimidinamine
22. 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
23. N-(4-fluorophenyl)-4,5-dimethyl-6-[(1s)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]pyrimidin-2-amine
24. Hy-121851
25. Cs-0083547
26. Q16801000
27. 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl- 1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
28. 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydro-isoquinolin-2-yl) Pyrimidine
29. 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine
30. N-(4-fluorophenyl)-4,5-dimethyl-6-(1-methyl-3,4-dihydro-2(1h)-isoquinolinyl)-2-pyrimidinamine
31. N-(4-fluorophenyl)-5,6-dimethyl-4-((1rs)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl)pyrimidin-2-amine
32. N-(4-fluorophenyl)-5,6-dimethyl-4-(1-methyl-3,4-dihydroisoquinolin-2(1h)-yl)pyrimidin-2-amine, (+/-)-
| Molecular Weight | 362.4 g/mol |
|---|---|
| Molecular Formula | C22H23FN4 |
| XLogP3 | 5.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 3 |
| Exact Mass | 362.19067491 g/mol |
| Monoisotopic Mass | 362.19067491 g/mol |
| Topological Polar Surface Area | 41 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 481 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
A Revaprazan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Revaprazan, including repackagers and relabelers. The FDA regulates Revaprazan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Revaprazan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Revaprazan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Revaprazan supplier is an individual or a company that provides Revaprazan active pharmaceutical ingredient (API) or Revaprazan finished formulations upon request. The Revaprazan suppliers may include Revaprazan API manufacturers, exporters, distributors and traders.
click here to find a list of Revaprazan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Revaprazan Drug Master File in Korea (Revaprazan KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Revaprazan. The MFDS reviews the Revaprazan KDMF as part of the drug registration process and uses the information provided in the Revaprazan KDMF to evaluate the safety and efficacy of the drug.
After submitting a Revaprazan KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Revaprazan API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Revaprazan suppliers with KDMF on PharmaCompass.
Revaprazan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Revaprazan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Revaprazan GMP manufacturer or Revaprazan GMP API supplier for your needs.
A Revaprazan CoA (Certificate of Analysis) is a formal document that attests to Revaprazan's compliance with Revaprazan specifications and serves as a tool for batch-level quality control.
Revaprazan CoA mostly includes findings from lab analyses of a specific batch. For each Revaprazan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Revaprazan may be tested according to a variety of international standards, such as European Pharmacopoeia (Revaprazan EP), Revaprazan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Revaprazan USP).
LOOKING FOR A SUPPLIER?
